ライフサイエンスコーパス: radioimmunotherapy

1 th beta- and alpha-emitter radionuclides for radioimmunotherapy.

2 ion therapy followed by ibritumomab tiuxetan radioimmunotherapy.

3 cells: targeted nanospheres and pretargeted radioimmunotherapy.

4 or dose than is possible with nonpretargeted radioimmunotherapy.

5 cute leukemias administered externally or as radioimmunotherapy.

6 with antibody drug conjugates, and dosing in radioimmunotherapy.

7 tory to rituximab and either chemotherapy or radioimmunotherapy.

8 Bone marrow is usually dose-limiting for radioimmunotherapy.

9 onitor the therapeutic effect of pretargeted radioimmunotherapy.

10 harmaceuticals; 37.9% did not treat NHL with radioimmunotherapy.

11 r institution accepted Medicare patients for radioimmunotherapy.

12 ne for a more informed design of combination radioimmunotherapy.

13 tial to be more effective than standard-dose radioimmunotherapy.

14 n tumors typically drops significantly after radioimmunotherapy.

15 ng the response of non-Hodgkin's lymphoma to radioimmunotherapy.

16 ease toxicity of subsequent (131)I-rituximab radioimmunotherapy.

17 before radioimmunotherapy and at 12 wk after radioimmunotherapy.

18 brane antigen, has potential as an agent for radioimmunotherapy.

19 , such as with immunoSPECT and immunoPET, or radioimmunotherapy.

20 L) after treatment with ibritumomab tiuxetan radioimmunotherapy.

21 -Fc H310A/H435Q as a promising candidate for radioimmunotherapy.

22 NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy.

23 ith multistep immune targeting approaches to radioimmunotherapy.

24 phoma has led to a resurgence of interest in radioimmunotherapy.

25 arted induction treatment; 57 (80%) received radioimmunotherapy.

26 ionuclides, as currently practiced in cancer radioimmunotherapy.

27 rter residence time that limits their use in radioimmunotherapy.

28 ecules can be used as effective vehicles for radioimmunotherapy.

29 xamined in patients with lymphoma treated by radioimmunotherapy.

30 3, and J591) and their potential utility for radioimmunotherapy.

31 targeting may be involved in the success of radioimmunotherapy.

32 e myeloid leukaemia 5 months after receiving radioimmunotherapy.

33 otherapeutically enhanced hK2 targeted alpha-radioimmunotherapy.

34 Analyses included only patients who received radioimmunotherapy.

35 ostic and radiotherapeutic agents for PET or radioimmunotherapy.

36 ive of improved PFS after (131)I-tositumomab radioimmunotherapy.

37 he clinically emerging method of pretargeted radioimmunotherapy.

38 linical biodistribution studies and clinical radioimmunotherapies.

39 was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval

40 diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical

41 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained re

42 d antibody combinations is crucial to making radioimmunotherapy a standard therapeutic modality.

43 6 received autologous HCT 3 d after (211)At-radioimmunotherapy, after lymph node and bone marrow bio

44 oal of this work was to determine an optimal radioimmunotherapy agent for further development against

45 p53-negative tumor-bearing mice treated with radioimmunotherapy alone or combined with cisplatin show

46 HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in combination with cisplati

47 ately 30% of its maximum tolerated dose, and radioimmunotherapy alone, at its maximum tolerated dose,

48 Alpha-radioimmunotherapy (alpha-RIT) represents an attractive

49 alpha-radioimmunotherapy (alpha-RIT) represents an attractive

50 New technologies, such as pretargeted radioimmunotherapy, also hold promise by reducing toxici

51 Radioimmunotherapy, an approach using radiolabeled antib

52 ty-six patients received full-radiation-dose radioimmunotherapy and 12 received attenuated doses beca

53 0) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy

54 greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities.

55 -PD-L1 antibody for radionuclide imaging and radioimmunotherapy and highlight a new opportunity to op

56 In this study, we used EGFR as a target for radioimmunotherapy and hypothesized that EGFR-directed r

57 Radioimmunotherapy and nuclear imaging (immuno-PET/SPECT

58 Pretargeting provides an alternative radioimmunotherapy and nuclear imaging strategy by overc

59 ysplastic syndrome 28 months after receiving radioimmunotherapy and one patient developed acute myelo

60 t predosing with unlabeled veltuzumab had on radioimmunotherapy and PT-RAIT targeting.

61 , and increased apoptosis were observed with radioimmunotherapy and the combination therapy.

62 vivo purging with rituximab, the utility of radioimmunotherapy and, finally, the evolving strategy o

63 esponse in two (both treated with additional radioimmunotherapy) and a mixed response in the remainin

64 ed systems, lessons learned from pretargeted radioimmunotherapy, and important considerations for har

65 ed immunotherapy with monoclonal antibodies, radioimmunotherapy, and T-cell therapies.

66 pretargeted radioimmunotherapy (PT-RAIT) or radioimmunotherapy, and tumor growth was monitored.

67 hese larger formats may be more suitable for radioimmunotherapy applications, evidenced by the precli

68 ent option, the responses of solid tumors to radioimmunotherapy are discouraging.

69 ive allogeneic transplantation and high-dose radioimmunotherapy are topics of ongoing investigation.

70 The 12-wk overall response rate to radioimmunotherapy based on IWC was 42% (14/33); complet

71 als of nonmyeloablative transplantation with radioimmunotherapy-based conditioning.

72 toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential

73 umor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0.

74 es could potentially play a valuable role in radioimmunotherapy by more stably encapsulating radionuc

75 ates the opinions and patterns of the use of radioimmunotherapy by nuclear physicians, affiliated res

76 the potential for improving the efficacy of radioimmunotherapy by targeting other NHL cell surface a

77 ctivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfus

78 otherapy and hypothesized that EGFR-directed radioimmunotherapy can deliver a continuous lethal radia

79 Radioimmunotherapy can effectively treat leptomeningeal

80 re eradicated in mice treated with anti-EGFR radioimmunotherapy combined with chemotherapy and PARP i

81 n are comparable to doses reported for other radioimmunotherapy compounds.

82 The therapeutic effect of radioimmunotherapy depends on the distribution of the ab

83 success of antibody-based immunotherapy and radioimmunotherapy directed at single targets (eg, GD2 a

84 Here, we address the question of radioimmunotherapy efficacy in MM minimal residual disea

85 y (mAb; CA12.10C12) protein dose for (211)At-radioimmunotherapy, extending the analysis to include in

86 valuate and optimize various intraperitoneal radioimmunotherapies for micrometastatic tumors.

87 lenge, rendering (225)Ac@GNTs candidates for radioimmunotherapy for delivery of (225)Ac(3+) ions at h

88 nt the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia.

89 le and 13 female; median age, 64 y) received radioimmunotherapy for NHL (20 received (90)Y-ibritumoma

90 Responders who did not administer radioimmunotherapy for NHL thought it took too much time

91 tant role for subgroups in the perception of radioimmunotherapy for NHL.

92 Radioimmunotherapy for non-Hodgkin's lymphoma often resu

93 of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and adnexal non-Hodgkin's

94 antibody 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors.

95 etry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion.

96 n lymphoma patients after (131)I-tositumomab radioimmunotherapy for potential use in treatment planni

97 viously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients.

98 The success of radioimmunotherapy for solid tumors remains elusive due

99 rove the efficacy and reduce the toxicity of radioimmunotherapy for the management of cancer.

100 mbination therapies using systemic anti-EGFR radioimmunotherapy for the treatment of recurrent and me

101 eview will present the latest information on radioimmunotherapy for treatment of hematologic malignan

102 c information useful for titrating doses for radioimmunotherapy, for patient risk stratification and

103 m baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51+/-4.05 to 3.94+/-4.41; P<0

104 Standard doses of radioimmunotherapy given as a conditioning regimen for h

105 em-cell transplant or myeloablative doses of radioimmunotherapy given in conjunction with stem-cell s

106 owed delayed tumor growth in the pretargeted radioimmunotherapy group, corresponding with their prolo

107 d consolidation as a possible indication for radioimmunotherapy had significantly fewer concerns abou

108 ividuals who perceived a negative future for radioimmunotherapy had significantly more concerns about

109 The safety and efficacy of radioimmunotherapy has been demonstrated for patients wi

110 The use of radioimmunotherapy has been evaluated in the treatment o

111 Radioimmunotherapy has been successfully used in the tre

112 Radioimmunotherapy has emerged as one of the most promis

113 Because radioimmunotherapy has resulted in long-term survival of

114 alpha-Particle emitter (213)Bi-based radioimmunotherapy has shown efficacy in a variety of me

115 therapies, both unconjugated antibodies and radioimmunotherapy, have had a significant impact on the

116 ioimmunotherapy predicted a higher growth of radioimmunotherapy if they could administer it in their

117 We explored i.p. radioimmunotherapy in a mouse model of human ovarian can

118 an intravenous fractionated regimen of alpha-radioimmunotherapy in a subcutaneous tumor model in mice

119 In this first preclinical study of anti-EGFR radioimmunotherapy in breast cancer, we found that anti-

120 n vivo purging with rituximab and the use of radioimmunotherapy in conditioning regimens may further

121 ficacy with the combination of cetuximab and radioimmunotherapy in CRC, which could potentially trans

122 ovide a foundation for maximising the use of radioimmunotherapy in disease control, designing future

123 role of kinetic and transport parameters of radioimmunotherapy in maximizing the therapeutic ratio,

124 an cancer, which may be generalized to alpha-radioimmunotherapy in other solid tumors.

125 atuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapsed CD22-positi

126 at have paved the way to an understanding of radioimmunotherapy in solid tumors.

127 atients with non-Hodgkin lymphoma (NHL) with radioimmunotherapy in the last 24 mo.

128 erred patients with non-Hodgkin lymphoma for radioimmunotherapy in the last 24 mo.

129 nical trials and reinvigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, par

130 and medical oncologists about CD20-directed radioimmunotherapy in the United States.

131 on make tomoregulin an attractive target for radioimmunotherapy, in which tomoregulin-specific antibo

132 scientific concerns, barriers to the use of radioimmunotherapy included difficulty in referral, perc

133 White blood cell count analysis after alpha-radioimmunotherapy indicated bone marrow recovery for th

134 Radioimmunotherapy infusion was overall well tolerated.

135 rapy data, and accelerating discovery within radioimmunotherapy interventions for HNSCC.

136 The increased uptake of radioimmunotherapy into the tumor resulted in >400% incr

137 w (RM) is often the primary organ at risk in radioimmunotherapy; irradiation of marrow may induce sho

138 Radioimmunotherapy is an effective treatment for non-Hod

139 Radioimmunotherapy is approved by the Food and Drug Admi

140 Radioimmunotherapy is considered to have great potential

141 Anti-CD20 radioimmunotherapy is effective in patients who have had

142 Radioimmunotherapy is emerging as an attractive alternat

143 py in breast cancer, we found that anti-EGFR radioimmunotherapy is safe and that TNBC orthotopic tumo

144 ubsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown.

145 table response rates have been observed when radioimmunotherapy is used as front-line treatment in pa

146 (90)Y-DOTA-epratuzumab radioimmunotherapy is well tolerated.

147 directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regime

148 For the growth of radioimmunotherapy, it appears crucial not only to demon

149 The amount of radioactivity for radioimmunotherapy may be determined by several methods,

150 Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abn

151 In radioimmunotherapy, myelotoxicity due to bone marrow rad

152 In patients who progress after radioimmunotherapy, new sites of disease commonly develo

153 t of these bsRICs for dual-receptor-targeted radioimmunotherapy of BC coexpressing HER2 and EGFR, inc

154 Radioimmunotherapy of cancer with radiolabeled antibodie

155 which has shown promise for PET imaging and radioimmunotherapy of cancer.

156 mply that the optimal strategy for A33-based radioimmunotherapy of colon cancer will consist of a mul

157 Whereas radioimmunotherapy of hematologic malignancies has evolv

158 subunit, as a favorable target for systemic radioimmunotherapy of HL.

159 the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for de

160 adiolabeled mAb-PAM4 for nuclear imaging and radioimmunotherapy of pancreatic carcinoma.

161 clearly validate tomoregulin as a target for radioimmunotherapy of prostate cancer.

162 essed molecule, tomoregulin, as a target for radioimmunotherapy of prostate cancer.

163 Success in the radioimmunotherapy of solid tumors has lagged because of

164 Radioimmunotherapy of solid tumors using antibody-target

165 g proteins may be superior to antibodies for radioimmunotherapy of solid tumors.

166 h the radiobiologic paradigms for successful radioimmunotherapy of solid tumors.

167 tibody that pretargeted (90)Y-hapten-peptide radioimmunotherapy or a directly radiolabeled, humanized

168 lymphoma and can be used in combination with radioimmunotherapy or standard chemotherapy for a more d

169 safety during infusions and regularly after radioimmunotherapy over a 6-month period.

170 thought it took too much time to administer radioimmunotherapy (P < 0.01) and had concerns about the

171 own practices if they referred patients for radioimmunotherapy (P < 0.01).

172 tion process (P < 0.05) and the high cost of radioimmunotherapy (P < 0.05).

173 0.01), regardless of response at 12 wk after radioimmunotherapy (P<or=0.02).

174 Finally, the 3D methods were applied to a radioimmunotherapy patient, and the mean tumor absorbed

175 efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metast

176 Initial response assessments 12 wk after radioimmunotherapy predict longer-term response.

177 with a positive outlook about the future of radioimmunotherapy predicted a higher growth of radioimm

178 report a theranostic approach to pretargeted radioimmunotherapy (PRIT) based on a pair of radioisotop

179 We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional rad

180 Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable ef

181 Pretargeted radioimmunotherapy (PRIT) has the potential to increase

182 Pretargeted radioimmunotherapy (PRIT) is designed to enhance the dir

183 recently reported a novel 3-step pretargeted radioimmunotherapy (PRIT) strategy based on a glycoprote

184 Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgk

185 Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (A

186 We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 anti

187 Pretargeted radioimmunotherapy (PRIT) using streptavidin (SA)-conjug

188 Pretargeted radioimmunotherapy (PRIT) with the beta-emitting radionu

189 e therapy, can potentially be used to design radioimmunotherapy protocols to improve efficacy.

190 ies alone or in combination with pretargeted radioimmunotherapy (PT-RAIT) or radioimmunotherapy, and

191 tetraacetic acid-di-HSG-peptide (pretargeted radioimmunotherapy [PT-RAIT]).

192 safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed

193 improved therapeutic index with pretargeted radioimmunotherapy (RAIT) using a DNL-constructed tri-Fa

194 w that anti-GPA33 DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal

195 The tositumomab/(131)I-tositumomab radioimmunotherapy regimen is administered as a dosimetr

196 However, optimal radioimmunotherapy regimens might call for the redefinit

197 t3 ligand were also measured to evaluate the radioimmunotherapy-related myelotoxicity.

198 Radioimmunotherapy represents a potential option as cons

199 s the most current allogeneic HCT data using radioimmunotherapy (RIT) and focuses on recent trials in

200 Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation

201 The usefulness of radioimmunotherapy (RIT) for infectious diseases was rec

202 The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-

203 Radioimmunotherapy (RIT) for pediatric tumors remains in

204 was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients

205 Radioimmunotherapy (RIT) for treatment of hematologic ma

206 e treatment of non-Hodgkin's lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a ne

207 ry radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacyto

208 (375 mg/m(2)) and proceeded to fractionated radioimmunotherapy (RIT) only if a repeat BM biopsy demo

209 Radioimmunotherapy (RIT) options for T-cell non-Hodgkin

210 Radioimmunotherapy (RIT) prolongs the survival of mice i

211 d a conditioning regimen employing anti-CD45 radioimmunotherapy (RIT) replacing total body irradiatio

212 Radioimmunotherapy (RIT) using (131)I-tositumomab has be

213 anti-DR) antibodies (Abs) and of pretargeted radioimmunotherapy (RIT) using Ab-streptavidin (SA) conj

214 Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comp

215 Radioimmunotherapy (RIT) using monoclonal antibodies lab

216 ium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for rela

217 S-17 tumor-bearing SCID mice and followed by radioimmunotherapy (RIT) with 177Lutetium-2G11 and safet

218 Radioimmunotherapy (RIT) with alpha-emitting radionuclid

219 One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal

220 targeting and tumor control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting

221 ed with either external beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of

222 vasive cancer radioimmunodetection (RID) and radioimmunotherapy (RIT).

223 on with tositumomab/iodine I-131 tositumomab radioimmunotherapy (RIT).

224 radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]).

225 An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand t

226 als are currently underway to further define radioimmunotherapy's role in the treatment of lymphomas.

227 In contrast, radioimmunotherapy should still be efficacious in metast

228 rt prolongs remission and consolidation with radioimmunotherapy shows promise.

229 d with monotherapy, combining cetuximab with radioimmunotherapy significantly and synergistically red

230 Results: (225)Ac-labeled DOTAylated-huCC49 radioimmunotherapy significantly reduced tumor growth in

231 Radioimmunotherapy studies in p53-positive HCT116 tumor-

232 In addition, a radioimmunotherapy study, using the anti-uPAR antibodies

233 After radioimmunotherapy, SUVlean max was lower for responders

234 inal half-life and serum clearance suited to radioimmunotherapy (T1/2beta, 100.24 +/- 20.92 h, and cl

235 In 2 patients, radioimmunotherapy targeting CD20 or CD66 was added to e

236 d comparative assessments using conventional radioimmunotherapy targeting CD20, CD22, and HLA-DR on h

237 alpha-radioimmunotherapy targeting CD45 may substitute for tot

238 meters and may be particularly effective for radioimmunotherapy targeting minimal residual disease (M

239 Radioimmunotherapy, targeting the CD20 antigen, in B-cel

240 In high-dose radioimmunotherapy, the importance of patient-specific d

241 derable success in improving the efficacy of radioimmunotherapy, the pretargeting strategy remains un

242 dies targeting lymphoma-associated antigens, radioimmunotherapy, therapeutic vaccination and allogene

243 Radioimmunotherapy toxicity consisted of grade 3-4 throm

244 e tumor absorbed radiation doses in STI571 + radioimmunotherapy-treated mice compared with PBS + radi

245 munotherapy-treated mice compared with PBS + radioimmunotherapy-treated mice.

246 reason for the growth arrest of the STI571 + radioimmunotherapy-treated tumors.

247 atients in the phase I trial of intra-Ommaya radioimmunotherapy using (131)I-3F8.

248 Myeloablative radioimmunotherapy using (131)I-tositumomab (anti-CD20)

249 Therefore, EGFR-directed radioimmunotherapy using (90)Y-Y-CHX-A''-DTPA-cetuximab

250 Early results from radioimmunotherapy using 8H9 have shown promise in patie

251 unotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent singl

252 Radioimmunotherapy using alpha-emitters such as (213)Bi,

253 Despite the promise of radioimmunotherapy using anti-CD20 antibodies (Ab) for t

254 These data suggest that conventional radioimmunotherapy using anti-CD20, anti-HLA-DR, or anti

255 assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tet

256 eutic efficacy of beta- versus alpha-emitter radioimmunotherapy using radiolabeled DOTA-daratumumab i

257 Radioimmunotherapy using targeted monoclonal antibodies

258 ated the preclinical efficacy of combination radioimmunotherapy, using a humanized (131)I-labeled ant

259 bolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean m

260 Radioimmunotherapy was generally viewed positively by re

261 Radioimmunotherapy was generally viewed positively by th

262 n percentage decline in platelet count after radioimmunotherapy was greater in the (90)Y-ibritumomab

263 Radioimmunotherapy was performed 10 d after 5T33 cell en

264 ed survey with 13 broad questions related to radioimmunotherapy was sent electronically to 13,221 Soc

265 various sizes after intraperitoneal (211)At-radioimmunotherapy, we used an in-house-developed Monte

266 emarkable improvements in tumor responses to radioimmunotherapy were discovered after the inclusion o

267 SPECT to monitor the response to pretargeted radioimmunotherapy were examined.

268 tracer infusion of (131)I-tositumomab before radioimmunotherapy were reviewed.

269 Results: RLT and additional radioimmunotherapy were well tolerated, without any acut

270 this study was to determine the efficacy of radioimmunotherapy when using (90)Y-labeled cetuximab an

271 trials have shown the promise of pretargeted radioimmunotherapy, which leverages the specificity of a

272 Clinical radioimmunotherapies with anti-CD20 monoclonal antibodie

273 umor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)Lu-cG250 than for radioimmu

274 vity of (111)In-cG250 (185 MBq), followed by radioimmunotherapy with (177)Lu-cG250.

275 s to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250.

276 predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250.

277 cts on tumor growth after fractionated alpha-radioimmunotherapy with (211)At-MX35-F(ab')2 was strong

278 cts on tumor growth after fractionated alpha-radioimmunotherapy with (211)At-MX35-F(ab')2 was strong

279 Radioimmunotherapy with (225)Ac-E4G10 was performed in N

280 Radioimmunotherapy with (64)Cu was highly effective in a

281 e examine the role of p53 in the response to radioimmunotherapy with (64)Cu-DOTA-cetuximab in KRAS-mu

282 dioimmunotherapy with (177)Lu-cG250 than for radioimmunotherapy with (90)Y-cG250, indicating that (17

283 INTERPRETATION: Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan mig

284 Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan mig

285 Dosimetric projections for radioimmunotherapy with (90)Y-labeled J591 suggested sim

286 used to generate dosimetric projections for radioimmunotherapy with (90)Y-labeled J591.

287 (211)At-anti-CD45 radioimmunotherapy with 0.75 mg mAb/kg efficiently targe

288 Recent data suggest that radioimmunotherapy with 131I-tositumomab or 90Y-ibritumo

289 This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplanta

290 Alternatively, radioimmunotherapy with alpha-emitters offers the advant

291 ternal gamma-beam radiation, we investigated radioimmunotherapy with an anti-CD45 mAb labeled with th

292 a dose of 2 mCi/kg Bi, further trials using radioimmunotherapy with Bi for nonmyeloablative HCT seem

293 study demonstrates that dose deescalation of radioimmunotherapy with Bi labeled to anti-CD45 or anti-

294 t (177)Lu has a wider therapeutic window for radioimmunotherapy with cG250 than (90)Y.

295 the authors demonstrated that pretransplant radioimmunotherapy with the alpha-emitter bismuth-213 (B

296 R could be treated by dual-receptor-targeted radioimmunotherapy with these bsRICs labeled with the be

297 he limitations of conventional, or one-step, radioimmunotherapy, with initial preclinical and clinica

298 Almost 30% (29.6%) of the responders thought radioimmunotherapy would probably grow and 38.0% thought

299 Seventy-nine (36.6%) responders thought radioimmunotherapy would probably grow in importance, an

300 The optimal antibody mass for radioimmunotherapy would therefore appear to be greater